Sandbox Reserved 1734

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Line 5: Line 5:
You may include any references to papers as in: the use of JSmol in Proteopedia <ref>DOI 10.1002/ijch.201300024</ref> or to the article describing Jmol <ref>PMID:21638687</ref> to the rescue.
You may include any references to papers as in: the use of JSmol in Proteopedia <ref>DOI 10.1002/ijch.201300024</ref> or to the article describing Jmol <ref>PMID:21638687</ref> to the rescue.
-
'''== Function ==''' Catalyzes the hydroxylation reaction to the amino acid L-Phenylalanine to L-Tyrosine. Catalyzes the rate-limiting step in the phenylalanine catabolism. Para-hydroxylation of the aromatic side-chain (rate-limiting step and the initial step). Catalyzes the hydroxylation of its substrate by incorporation of one oxygen atom into the aromatic ring, and the final reaction includes the reduction of the 2nd oxygen atom to water using electrons supplied by BH4. A metabolic enzyme involved in catabolism of L-Phe in the liver. This enzyme is responsible for the first step in processing phenylalanine, which is a building block of proteins obtained through the diet.
+
== Function == Catalyzes the hydroxylation reaction to the amino acid L-Phenylalanine to L-Tyrosine. Catalyzes the rate-limiting step in the phenylalanine catabolism. Para-hydroxylation of the aromatic side-chain (rate-limiting step and the initial step). Catalyzes the hydroxylation of its substrate by incorporation of one oxygen atom into the aromatic ring, and the final reaction includes the reduction of the 2nd oxygen atom to water using electrons supplied by BH4. A metabolic enzyme involved in catabolism of L-Phe in the liver. This enzyme is responsible for the first step in processing phenylalanine, which is a building block of proteins obtained through the diet.
BH4 functions as a co-substrate that is hydroxylated at each turnover to pterin-4a-carbinolamine (4a-OH-BH4), with consequent dissociation from the enzymes. The major regulatory mechanisms of PAH include activation of phenylalanine inhibition by BH4, and additional activation by phosphorylation. Substrate activation and positive cooperativity for Phe binding involves all 3 functional domains and all four subunits in the holoenzyme. Phe binds between the regulatory domain and the interacting catalytic domain, near the sequence binding motif. Hypothesized causes of Phe activation mechanism: Homotropic binding of Phe at active site and the regulatory domain is involved in cooperativity through the interactions with the catalytic and oligomerization domains. Phe binds to an allosteric site, besides the active site, on the regulatory domain, inducing large conformational changes. The allosteric. regulation is necessary to maintain Phe below neurotoxic levels. BH4 acts as a negative regulator by blocking Phe activation, however, BH4 binding to a Phe-activated form of PAH results in positive cooperativity. Phosphorylation acts as mediator of Phe activation by decreasing Phe concentration required to activate enzyme phosphorylation at Ser16.
BH4 functions as a co-substrate that is hydroxylated at each turnover to pterin-4a-carbinolamine (4a-OH-BH4), with consequent dissociation from the enzymes. The major regulatory mechanisms of PAH include activation of phenylalanine inhibition by BH4, and additional activation by phosphorylation. Substrate activation and positive cooperativity for Phe binding involves all 3 functional domains and all four subunits in the holoenzyme. Phe binds between the regulatory domain and the interacting catalytic domain, near the sequence binding motif. Hypothesized causes of Phe activation mechanism: Homotropic binding of Phe at active site and the regulatory domain is involved in cooperativity through the interactions with the catalytic and oligomerization domains. Phe binds to an allosteric site, besides the active site, on the regulatory domain, inducing large conformational changes. The allosteric. regulation is necessary to maintain Phe below neurotoxic levels. BH4 acts as a negative regulator by blocking Phe activation, however, BH4 binding to a Phe-activated form of PAH results in positive cooperativity. Phosphorylation acts as mediator of Phe activation by decreasing Phe concentration required to activate enzyme phosphorylation at Ser16.
-
'''==Function in the body/ Disease==''' L-Tyrosine is the precursor to neurotransmitters such as epinephrine, dopamine, and serotonin. PAH depletion or mutation leads to excessive accumulation of toxic L-Phe levels (physiological plasmatic levels <120 micromolar) This causes of the autosomal recessive metabolic disorder Phenylketonuria (PKU). PKU is a congenital disorder characterized by excessive amounts of L-Phenylalanine that buildup to neurotoxic amounts leading to cognitive disability and neurological impairment- profound mental retardation, seizures, microcephaly, and delayed development. The severity of mutation indicated the severity of PKU that leaded to increase the accumulation of phenylalanine in the patient blood with toxic effect. PAH secreted from the liver, and a variety of deficiency syndromes causing various levels of hyperphenylalaninemia have been observed in PKU patient. (Shebl 2019) finds, the most severe PKU was a 14-year-old female followed by a 6-month-old male and a 16-year-old male. Tyrosine biosynthesis as liver enzyme associated with melanin-associated physiological processes. Treatments include a lifelong diet avoiding foods containing phenylalanine and supplementation of synthetic formations of the cofactor tetrahydrobiopterin (BH4) PAH mutations result in reduced enzyme activity and stability and some alter its oligomeric state. Mutations spread throughout 3D structure, but most located in catalytic domain. Loss of enzymatic function caused mainly by folding defects leading to decreased stability. PAH proteins found in hepatocytes (liver cells). Found on chromosome 12 with 13 exons.
+
== Function in the body/ Disease == L-Tyrosine is the precursor to neurotransmitters such as epinephrine, dopamine, and serotonin. PAH depletion or mutation leads to excessive accumulation of toxic L-Phe levels (physiological plasmatic levels <120 micromolar) This causes of the autosomal recessive metabolic disorder Phenylketonuria (PKU). PKU is a congenital disorder characterized by excessive amounts of L-Phenylalanine that buildup to neurotoxic amounts leading to cognitive disability and neurological impairment- profound mental retardation, seizures, microcephaly, and delayed development. The severity of mutation indicated the severity of PKU that leaded to increase the accumulation of phenylalanine in the patient blood with toxic effect. PAH secreted from the liver, and a variety of deficiency syndromes causing various levels of hyperphenylalaninemia have been observed in PKU patient. (Shebl 2019) finds, the most severe PKU was a 14-year-old female followed by a 6-month-old male and a 16-year-old male. Tyrosine biosynthesis as liver enzyme associated with melanin-associated physiological processes. Treatments include a lifelong diet avoiding foods containing phenylalanine and supplementation of synthetic formations of the cofactor tetrahydrobiopterin (BH4) PAH mutations result in reduced enzyme activity and stability and some alter its oligomeric state. Mutations spread throughout 3D structure, but most located in catalytic domain. Loss of enzymatic function caused mainly by folding defects leading to decreased stability. PAH proteins found in hepatocytes (liver cells). Found on chromosome 12 with 13 exons.
-
==Structure== Primary Structure:
+
== Structure == Primary Structure:
452 residues/monomer
452 residues/monomer
Around 52kDa/monomer
Around 52kDa/monomer

Revision as of 13:55, 7 November 2022

This Sandbox is Reserved from August 30, 2022 through May 31, 2023 for use in the course Biochemistry I taught by Kimberly Lane at the Radford University, Radford, VA, USA. This reservation includes Sandbox Reserved 1730 through Sandbox Reserved 1749.
To get started:
  • Click the edit this page tab at the top. Click on Show preview and then Save the page after each step, then edit it again.
  • show the Scene authoring tools, create a molecular scene, and save it. Copy the green link into the page.
  • Add a description of your scene. Use the buttons above the wikitext box for bold, italics, links, headlines, etc.

More help: Help:Editing

Your Heading Here (maybe something like 'Structure')

Caption for this structure

Drag the structure with the mouse to rotate

References

  1. Hanson, R. M., Prilusky, J., Renjian, Z., Nakane, T. and Sussman, J. L. (2013), JSmol and the Next-Generation Web-Based Representation of 3D Molecular Structure as Applied to Proteopedia. Isr. J. Chem., 53:207-216. doi:http://dx.doi.org/10.1002/ijch.201300024
  2. Herraez A. Biomolecules in the computer: Jmol to the rescue. Biochem Mol Biol Educ. 2006 Jul;34(4):255-61. doi: 10.1002/bmb.2006.494034042644. PMID:21638687 doi:10.1002/bmb.2006.494034042644
Personal tools